Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 7/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237497 | 0.82 | MAPK14 (0.44) | MAPK14MMP13 | |
| SCHEMBL3608651 | 0.79 | ROCK1 (0.60) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL18352279 | 0.75 | MAPK14 (0.58) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL29351167 | 0.75 | MAPK14 (0.58) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL3235973 | 0.73 | THRA (0.39) | ROCK2 | |
| SCHEMBL29351162 | 0.72 | MAPK14 (0.57) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL1114287 | 0.71 | ROCK2 (0.52) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL1114331 | 0.70 | ROCK2 (0.53) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL3242043 | 0.70 | ROCK1 (0.53) | ROCK1ROCK2MAPK14MMP13GLS | |
| SCHEMBL1114587 | 0.70 | ROCK2 (0.48) | ROCK1ROCK2MAPK14MMP13GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | claimed |
| WO-2009131952-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING THIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| WO-2009131952-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING THIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | ROCK1 2801/4885ROCK2 3358/4885MAPK14 3946/4885 |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | CFTR, PKD1, PKD2 | ROCK1 2497/4885ROCK2 2835/4885MAPK14 4269/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | ROCK1 2801/4885ROCK2 3358/4885MAPK14 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.